Yupelri: payments to doctors
Payments that named Yupelri as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $9.7M
- Providers
- 36,461
- Transactions
- 172,512
- Average per transaction
- $56
The per-transaction average — $56 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 36,461 providers the average total is $266, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Mylan Specialty L.p. | $8,350,234 | 86.1% |
| Viatris Specialty LLC | $1,227,162 | 12.7% |
| Mylan Inc. | $102,227 | 1.1% |
| Mylan Pharmaceuticals Inc. | $11,718 | 0.1% |
| Mylan LLC | $2,969 | 0.0% |